RT Journal Article
SR Electronic
T1 Biodistribution and Radiation Dosimetry of the Dopamine D<sub>2</sub> Ligand <sup>11</sup>C-Raclopride Determined from Human Whole-Body PET
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 313
OP 319
VO 47
IS 2
A1 Mark Slifstein
A1 Dah-Ren Hwang
A1 Diana Martinez
A1 Jesper Ekelund
A1 Yiyun Huang
A1 Elizabeth Hackett
A1 Anissa Abi-Dargham
A1 Marc Laruelle
YR 2006
UL http://jnm.snmjournals.org/content/47/2/313.abstract
AB Whole-body radiation dosimetry of 11C-raclopride was performed in healthy human volunteers. Methods: Subjects (n = 6) were scanned with PET. Subjects received single-bolus injections of 11C-raclopride (S-(−)-3,5-dichloro-N-[(1-ethyl-2-pyrrolidinyl)]methyl-2-hydroxy-6-methoxybenzamide) (533 ± 104 MBq) and were scanned for approximately 110 min with a 2-dimensional whole-body protocol. Regions of interest were placed over all visually identifiable organs and time–activity curves were generated. Residence times were computed as the area under the curve of the time–activity curves, normalized to injected activities and standard values of organ volumes. Absorbed doses were computed according to the MIRD schema with MIRDOSE3.1 software. Results: Organs with the highest radiation burden were gallbladder wall, small intestine, liver, and urinary bladder wall. Conclusion: On the basis of the estimated absorbed dose, the maximum allowable single study dose under U.S. federal regulations for studies performed under Radiation Drug Research Committee is 1.58 GBq (42.8 mCi). This is still considerably higher than the doses of 11C-raclopride commonly used in research PET (370−555 MBq).